Alkermes (ALKS) EBITDA Margin Growth (1y) (2011 - 2026)
Alkermes (ALKS) EBITDA Margin Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.67 Bn | 34.93 Bn | 1.97 Bn | 304.00 |
| 2 | Zoetis | 30.59 Bn | 28.65 Bn | 1.62 Bn | -157.00 |
| 3 | RedHill Biopharma | 26.22 Bn | 26.22 Bn | - | - |
| 4 | United Therapeutics | 23.80 Bn | 21.65 Bn | 648.10 Mn | -650.00 |
| 5 | Curaleaf Holdings | 23.70 Bn | 23.70 Bn | 157.29 Mn | -282.00 |
| 6 | Viatris | 18.69 Bn | 16.89 Bn | 1.16 Bn | 8,660.00 |
| 7 | Neurocrine Biosciences | 16.86 Bn | 15.54 Bn | 800.70 Mn | 2,080.00 |
| 8 | Elanco Animal Health | 11.99 Bn | 11.57 Bn | 785.00 Mn | 152.00 |
| 9 | Dr Reddys Laboratories | 11.65 Bn | 11.51 Bn | - | - |
| 10 | Alkermes | 94.96 Mn | -416.90 Mn | -116.06 Mn | -17,785.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17,785.00 |
| Dec 31, 2025 | -2,096.00 |
| Sep 30, 2025 | -441.00 |
| Jun 30, 2025 | -58.00 |
| Mar 31, 2025 | -287.00 |
| Dec 31, 2024 | 285.00 |
| Sep 30, 2024 | 1,260.00 |
| Jun 30, 2024 | -1,562.00 |
| Mar 31, 2024 | 2,396.00 |
| Dec 31, 2023 | 3,930.00 |
| Sep 30, 2023 | 208,549.00 |
| Jun 30, 2023 | 105,070.00 |
| Mar 31, 2023 | 92.00 |
| Dec 31, 2022 | -852.00 |
| Sep 30, 2022 | -206,265.00 |
| Jun 30, 2022 | -101,288.00 |
| Mar 31, 2022 | -535.00 |
| Dec 31, 2021 | 1,532.00 |
| Sep 30, 2021 | -964.00 |
| Jun 30, 2021 | 1,201.00 |